In October 2009, US FDA approved a new therapy for renal cell carcinoma. This was highlighted in Nature Reviews: Drug Discovery January, 2010 issue. Complete priscription information given on FDA web site.
Sunday, January 31, 2010
Pazopanib: A new drug for treating renal cell carcinoma
In October 2009, US FDA approved a new therapy for renal cell carcinoma. This was highlighted in Nature Reviews: Drug Discovery January, 2010 issue. Complete priscription information given on FDA web site.
Subscribe to:
Post Comments (Atom)
1 comment:
Pazopanib (brand name Votrient) is a powerful and selective multi targeted sensory receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a, and c-kit that blockings tumor development and reduces angiogenesis.
Post a Comment